Print version

pdf Click to download

Search Pub Med

Back
197P Queen Elizabeth II Conference Centre London
BPS Winter Meeting 2012

A comparison of novel NG, NG-disubstituted arginines on recombinant dimethylarginine dimethylaminohydrolase-1 activity and nitrite production in RAW264.7 macrophages.

C Morfill1, S Rossiter0,2, CL Smith1. 1University of Westminster, London, UK, 2University of Hertfordshire, Hatfield, UK

Endogenously occurring asymmetric dimethylarginine (ADMA) concentrations have been widely documented to increase in a range of cardiovascular conditions. One mechanism by which ADMA may act is through inhibition of nitric oxide synthases. Dimethylarginine dimethylaminohydrolases (DDAH) metabolise ADMA to form citrulline in vivo1 and have been considered as targets for modulating ADMA levels2.

Previously1,2 we found that arginine analogues with an NG-methoxyethyl substituent gave optimum inhibition with no effect on other arginine-processing enzymes2, 4. Closely related NG,NG-disubstituted arginines, i.e. direct analogues of ADMA, are also of interest for their potential as DDAH inhibitors, but few have been described in the literature. This study aims to evaluate the effects of NG,NG-disubstituted arginines on cell viability, inducible nitric oxide synthase activity and on DDAH1 activity to identify new lead compounds.

The desired analogues were not readily accessible by our previously published methods2, therefore, the methodology of Katritzkys group for preparation of trisubstituted guanidines from di-(benzotriazol-1-yl)methanimine 5 was adopted to give a short series of acyclic and cyclic NG, NG-disubstituted arginine analogues, using secondary amines and ornithine.

RAW264.7 cells in 96 well plates (1x104 cells/ well) were stimulated with LPS (1g/ml) in DMEM media (containing 10% FCS) and NG,NG-disubstituted arginines were added at 0.5-500 M. Nitrite secreted was measured using Greiss assay2 and cell viability was determined using MTT assay2.

Human DDAH1 (QIAgenes construct, Qiagen) was expressed in E. coliBL21(DE3). DDAH1 was purified using His-IDA (MacheryNagel). DDAH1 activity was measured using colorometic citrulline assay based on Knipp4. Assays contained ADMA (10mM) in sodium phosphate (10 mM pH8.0); symmetric dimethylarginine (10mM), not a substrate for DDAH1, was used as blank. Experiments were carried out in duplicate, and repeated on at least 3 separate occasions, and analysed by two-way ANOVA.

NG,NG-disubstituted arginine analogues substituted with morpholinyl, piperidinyl, methoxyethyl/methyl and N-methylpiperazinyl groups did not significantly alter cell viability, the pyrrolidinyl substituted analogue at 500M reduced cell viability to 39.2 5.73 % (% of control, untreated cells where n=3, p>0.001). There was no significant effect of the morpholinyl and N-methylpiperazinyl analogues on nitrite production in the LPS stimulated RAW264.7 cells. At 500 M the piperidinyl and the methoxyethyl/methyl analogues, respectively, reduced nitrite production in LPS stimulated RAW264.7 cells from 40.12 1.27M to 5.400.26 M (P<0.01, n=4) and 15.92 1.84 M (P<0.01, n=4).

The N-methylpiperazinyl analogue (100M) reduced DDAH1 activity to 26.99 12.75% of control (p=0.45, n=3), the acyclic methoxyethyl/methyl analogue and the morpholinyl analogue (shown to be a weak inhibitor in a previous study by Kotthaus6) had a modest inhibitory effect on DDAH 1 activity.

In summary, we have found that the cyclic NG, NG-(N-methylpiperazinyl) arginine analogue specifically inhibits DDAH1, without effecting nitrite production or cell viability, and is a novel and interesting lead compound.

1Leiper, J. (2007). Nat Med. 13:198-203.

2 Rossiter, S. et al. (2005). J Med Chem. 48: 4670-4678.

3Kotthaus, J et al. (2012) J Enz Inhib Med Chem. 27: 24-28

4Knipp, M & Vasak, M (2000).Anal Biochem. 286:257-64.

5 Katritzky, A (2000) J. Org. Chem. 65, 8080-8082.

6Kotthaus, J et al. (2008) Bioorg. Med. Chem. 16, 10205-10209.